Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: A decision analysis

Annals of Thoracic Surgery

Volumn 66, Issue 6, 1998, Pages 1876-1884

  Scott, Walter J ^a,b   Shepherd, James ^a,b   Gambhir, Sanjiv Sam ^a,b,c  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DIAGNOSTIC ACCURACY; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; MEDICARE; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REIMBURSEMENT;

EID: 0032451135     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(98)01055-8     Document Type: Article

References (24)

1. 1. Guhlmann A, Storck M, Kotzerke J, Moog F, Sunder-Plassman L, Reske SN. Lymph node staging in non-small cell lung cancer: evaluation by [18F] FDG positron emission tomography (PET). Thorax 1997;52:438-41.
2. 2. Bury T, Paulus P, Dowlati A, et al. Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. Eur Respir J 1996;9:2560-4.
3. 3. Scott WJ, Gobar LS, Terry JD, Dewan NA, Sutherland JJ. Mediastinal lymph node staging of non-small cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg 1996;111:642-8.
4. 4. Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995;60:1573-81.
5. 5. Scott WJ, Schwabe JL, Gupta NC, et al. Positron emission tomography of lung tumors and mediastinal lymph nodes using [18]fluorodeoxyglucose. Ann Thorac Surg 1994;58: 698-703.
6. 6. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small cell carcinoma. J Nucl Med 1996;37:1428-36.
7. 7. Pauker SG, Kassirer JP. Decision analysis. In: Bailar JC III, Mosteller F, eds. Medical uses of statistics. Boston, MA: NEJM Books, 1992:159-80.
8. 8. Weinstein M, Fineberg H. Clinical decision analysis. Philadelphia: WB Saunders, 1980.
9. 9. Gambhir SS, Gupta P, Shepherd JE, et al. Medical decision analysis tool: a new physician friendly decision tree tool. MD Computing 1998;15:40-8.
10. 10. Luke WP, Pearson FG, Todd TRJ, et al. Prospective evaluation of mediastinoscopy for assessment of carcinoma of the lung. J Thorac Cardiovasc Surg 1986;91:53-60.
11. 11. Gross B, Glazer G, Orringer M, Spizary D, Flint A. Bronchogenic carcinoma metastatic to normal-sized lymph nodes: frequency and significance. Radiology 1988;166:71-4.
12. 12. McLoud T, Bourgouin P, Greenberg R. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992;183:319-23.
13. 13. Dillemans B, Deneffe G, Verschakelen J, Decramer M. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. Eur J Cardiothorac Surg 1994;8:37-42.
14. 14. White P, Adams H, Crane M, Butchart E. Preoperative staging of carcinoma of the bronchus: can computed tomographic scanning reliably identify stage III tumors? Thorax 1994;49:951-7.
15. 15. Primack S, Lee K, Logan P. Bronchogenic carcinoma: utility of CT in the evaluation of patients with suspected lesions. Radiology 1994;193:795-800.
16. 16. Moses LE, Shapiro D. Combining independent studies of a diagnostic test into a summary ROC curve: data analytic approaches and some additional considerations. Stat Med 1993;12:1293-316.
17. 17. Ginsberg R, Hill I, Eagan R, et al. Modern thirty-day operative mortality for surgical resection in lung cancer. J Thorac Cardiovasc Surg 1983;86:654-8.
18. 18. Black WC, Armstrong P, Daniel T. Cost-effectiveness of chest CT in T1N0M0 lung cancer. Radiology 1988;167:373-8.
19. 19. Moroff S, Pauker S. What to do when the patient outlives the literature, or DEALE-ing with a full deck. Med Decis Making 1983;3:313-38.
20. 20. Cummings S, Illington G, Richard R. Managing solitary pulmonary nodules: the choice of strategy is a "close call." Am Rev Respir Dis 1986;134:453-60.
21. 21. Beck J, Pauker S, Gottlieb J. A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making. Am J Med 1982;73:883-97.
22. 22. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis: working papers series. Natl Bureau Econ Res 1992;4164:1-34.
23. 23. Patterson GA, Piazza D, Pearson FG, et al: Significance of metastatic disease in subaortic lymph node. Ann Thorac Surg 1987;43:155-8.
24. 24. Gambhir SS, Shepherd JE, Shah BD, et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 1998;16:2113-25.